Texas Oncology, PA

1. AstraZeneca Pharmaceuticals LP $2,842,393 106 payments
2. Eisai Inc. $677,322 685 payments
3. Celgene Corporation $412,879 11 payments
4. AstraZeneca UK Limited $282,593 19 payments
5. Merck Sharp & Dohme Corporation $272,894 47 payments
6. Novocure Inc. $173,723 86 payments
7. EMD Serono, Inc. $122,989 141 payments
8. Novocure GmbH $51,762 39 payments
9. Novartis Pharmaceuticals Corporation $28,330 2 payments
10. Acerta Pharma LLC $20,896 8 payments

1. A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) $1,142,096 6 payments
2. A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 $325,623 6 payments
3. A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) $305,819 430 payments
4. A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting $275,051 1 payment
5. A Single-arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease $270,134 130 payments
6. Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) $255,557 16 payments
7. A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) $252,734 4 payments
8. an observational,prospective,multicenter study of non small cell lung cancer patients in the US receiving standard of care and initiating an approved therapy with risk of pneumonitis ILD $204,363 10 payments
9. Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. $145,759 2 payments
10. EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. $126,079 59 payments

1. Patient care $22,819 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.